Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK1360707
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GSK1360707 is an investigational small molecule drug developed by GSK as a potent triple reuptake inhibitor, targeting the reuptake of dopamine, norepinephrine, and serotonin. It acts by inhibiting the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT), thereby increasing synaptic concentrations of these neurotransmitters in the brain. Preclinical studies demonstrated that GSK1360707 increases levels of all three monoamines in key brain regions associated with mood regulation and exhibits antidepressant-like effects in animal models. The drug was evaluated for its potential use in treating major depressive disorder (MDD) but has not advanced beyond early clinical trials[3][4][5].
- Other names
- 1013098-04-89DE44WJ46X
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on GSK1360707.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK1360707.